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THE EFFECT OF YOGA ON DEPRESSION IN MILD COGNITIVE 
IMPAIRMENT  
URVASHI K. SHUKLA 
ABSTRACT 
 Preclinical Alzheimer’s Disease (AD) appears after a decade or more of brain 
degeneration and this is termed mild cognitive impairment (MCI). As it progresses, 
patients begin to lose their short term memory, motor skills and begin to become more 
disoriented and bed ridden. Thus, early diagnosis becomes paramount in preventing 
eventual disability. Individuals with MCI may have advanced brain degeneration and the 
presence of neuropsychiatric symptoms (NPS) may augment the progression to AD 
dementia compared to individuals without NPS. Of these NPS, depression is one of the 
main symptoms that greatly impacts quality of life but it is often overlooked and 
undertreated. The annual cost of pharmacologic treatments is rising and assessment tools 
for AD and depression are increasing as are rates of AD. It is crucial to execute 
compelling non-pharmacologic interventions that can be beneficial to the elderly 
population while acknowledging their endurance, fitness and enjoyment levels. Yoga is 
one such intervention that has been proven to improve depression and cognitive levels 
while simultaneously maintaining a positive and engaging atmosphere. Studies have 
found that consistent use of yoga can also increase GABA levels in the brain which serve 
to improve depression levels too. There have been no studies that have investigated the 
effects of yoga on depression in individuals with mild cognitive impairment. 
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 This proposed trial will be a randomized controlled study and it will compare the 
quality of depression symptoms in elderly individuals with MCI and depression in elderly 
individuals without MCI with a yoga intervention combined with walking and in a 
control group with walking alone. Several assessment tools will be utilized to evaluate 
the outcomes including the PHQ-9, GDS, HAM-D, and MoCA. The effect on sleep will 
also be measured as a secondary outcome. If yoga is able to improve depression levels, it 
may have an impact in reversing MCI, delaying progression to AD dementia, and a 
potentially deep impact on the financial and public health burden of AD. Furthermore, it 
can reduce the need for anti-depressants and other medications for depression and 
eliminate their potentially harmful side effects. If this study proves to be clinically 
significant, yoga can also be recommended as an efficient intervention by clinicians in 
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 Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by 
progressive cognitive decline and neuropsychiatric symptoms, eventually causing 
complete dependence for basic functions of life. It is the most common cause of 
dementia, and it accounts for about 75% of all cases of AD. Currently, AD affects more 
than 5.5 million Americans but that number is projected to triple to 14 million by 2060. 
AD disproportionately afflicts minority ethnic groups with a worldwide population of 24 
million and affects more females than males.4, 6, 15AD is frequently associated with 
episodic memory impairment, executive and visuospatial functioning deficits, and 
neuropsychiatric symptoms (NPSs), such as depression, anxiety, apathy, irritability, and 
sleep disorder. 
 A prodromal phase of accelerated cognitive decline, known as mild cognitive 
impairment (MCI), precedes AD and acts as a translational stage to dementia with a 
conversion rate of 10-15% per year.11 MCI is characterized by cognitive impairments that 
are not severe enough to require help with activities of daily life. NPSs, particularly 
depression, are the earliest precursor signs of progression to dementia in MCI, yet they 
are under recognized and difficult to treat.  
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 Complex biological, genetic and structural constituents along with multifactorial 
risk factors encompass the pathogenesis of AD. Hallmarks of AD include neurofibrillary 
tangles and extracellular amyloid beta plaques in brain regions augmented by 
mitochondrial dysfunction causing oxidative stress and neuronal degeneration.6, 12, 13 
Genetic basis of AD is dependent on the type, Familial or Sporadic AD. Familial AD is 
rarer and is caused by mutations to Presenilin 1 (PS1), Presenilin 2 (PS2) and Amyloid 
Precursor Protein (APP). Sporadic AD affects more than 90% of AD patients and is 
found to be linked to the Apolipoprotein E (APOE) gene.9 Modifiable risk factors include 
cardiovascular disease, diabetes obesity, hypertension, hypercholesterolemia, metabolic 
syndrome, and stress; non-modifiable risk factors include age, sex, family history, and 
genetics.6, 11, 14, 16 
 Currently, there is no pharmacologic therapy to halt progression or cure AD and 
treatment relies solely on symptomatic management.25 Cholinesterase inhibitors and 
NMDA receptor temporarily aid with cognitive impairment but are associated with side 
effects and have not shown long- term promise. Moreover, clinical trials have not shown 
favorable results in these drugs halting progression of MCI to AD.8, 25 Drug therapy of 
NPSs is highly related to adverse effects.23, 24 Non-pharmacologic interventions for NPSs 
have gained increasing attention but it is unclear which is the most effective form. Some 
studies suggest that physical exercise in the form of dancing, walking, yoga or cognitive 
interventions, such as meditation and mindfulness, can provide short term benefits in 




Statement of the Problem 
 The prevalence of NPSs is between 43% and 59% in patients with MCI.21 Among 
these NPSs, depression greatly diminishes the quality of life of the elderly, prevents them 
from working and mingling, increases frustration levels, increases direct cost of care and 
institutionalization, and increases burden on their caregivers. Additionally, the 
combination of depression and MCI leads to a four-fold higher risk of progression to 
dementia.21 Consequently, early detection and treatment of depression in elderly 
individuals with MCI is imperative. Unfortunately, it is often undervalued, overlooked, 
presumed to be a normal part of aging, and challenging to treat. 
 There is no direct standard of pharmacotherapy for NPSs treatment. 
Antipsychotics, antidepressants, benzodiazepines, cholinesterase inhibitors and 
anticonvulsants are used with minimal efficacy, have several adverse side effects, and 
increase the risk of death. Due to the high prevalence of comorbidities in the elderly, 
medication interaction risks, and low risk benefits of pharmacologic treatment, non-
pharmacologic interventions such as yoga should be considered. The complexities of 
depression are interlinked with sleep disorder and, without proper treatment, worsening 
of all NPSs could result. While the use of yoga as a healthy form of exercise for the 
elderly has been recognized, further exploration is warranted regarding studies the effects 






Patients diagnosed both with MCI and depression participating in a yoga intervention 
twice a week with daily walking will have notable improvement in their depression levels 
after 3 months compared to patients who only execute daily walking.  
 
Objectives and specific aims 
The purpose of this research is to investigate whether a safe and manageable yoga routine 
can improve depressive symptoms in individuals diagnosed with mild cognitive 
impairment. If this study shows that yoga can improve depressive symptoms in mild 
cognitive impairment, it can be recommended by healthcare providers in individuals with 
mild cognitive impairment as a valid therapy. In a broader sense, yoga can also be 
incorporated as an exercise activity in senior activity centers and assisted living facilities. 
The specific aims of this thesis project include: 
 
• Performing a literature review to provide evidence for the potential of yoga to 
reduce depression  
• Proposing a randomized control trial to investigate the effectiveness of a twice a 
week yoga intervention for 3 months in improving depression in MCI patients 
• As a secondary measure within the proposed study, investigate the effect of yoga 
on sleep disorder in patients with MCI and depression 
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REVIEW OF THE LITERATURE 
OVERVIEW 
Epidemiology of Alzheimer’s Disease 
 There are currently more than 5.5 million Americans and 24 million people 
worldwide who are affected by Alzheimer’s disease (AD).6 According to the Centers for 
Disease Control and Prevention (CDC), that number is projected to triple to 14 million by 
2060. AD is the 6th leading cause of death in the country among adults and the 5th leading 
cause of death among adults aged 65 or older.17 Individuals between ages 60-85 have a 
15-fold higher risk of getting AD dementia. It is estimated that about 1/10 people age 65 
or older currently have AD dementia and 1/3 people age 85 or older have AD dementia.6, 
10 
 Cases of AD are increasing worldwide but the prevalence greatly varies among 
low, middle, and high income countries. The prevalence of AD is greater in developed 
countries. This is largely due to the fact that developed countries have more risk factors 
such as hypertension, obesity, smoking, diabetes, metabolic syndrome, and 
cerebrovascular disease than developing countries. The prevalence of AD is low in less 
developed areas, such as Africa and the Middle East, while rising in China, India and 
Latin America. 14 
 There are differences that exist in the epidemiology of AD among Whites, 
African Americans and Hispanics in the U.S., only a small fraction of which are 
accounted for by genetics.  Recent studies suggest that AD may disproportionately 
burden minority ethno-racial groups.4, 6 In individuals aged 65 and older, the prevalence 
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of AD dementia is: 13.8% in African Americans; 12.2% in Hispanics; 10.3% in non-
Hispanic whites 10.3%; 9.1% in American Indian and Alaska Natives; and 8.4% in Asian 
and Pacific Islanders. In terms of gender differences, several studies have consistently 
found that more women have AD than men most likely because women survive longer.15 
Definition of Alzheimer’s Disease (AD)  
 AD is a progressive neurodegenerative disorder that is characterized by 
progressive cognitive decline leading to complete dependence for basic functions of daily 
life. AD can be classified as either mild, moderate or severe (Table 1).11, 18 It is 
characterized by several cognitive and neuropsychiatric features and is the most common 
cause of dementia in 75% of cases.6, 11, 13 Certain cognitive features include: episodic 
memory impairment (poor new learning), language difficulties, executive function 
deficits and visuospatial functioning deficits. Individuals with AD often repeat stories, 
have difficulties with word finding, problems with expression, and impaired planning or 
multi-tasking judgement. Additionally, they have poor awareness and insight into these 
problems. 6, 10, 11, 16 
Table 1. Cognitive, functional and behavioral deficits by disease stage in 




Definition of MCI 
 The concept of MCI was first defined in 1962 as “benign senescent 
forgetfulness.” 28 In 1986, the National Institute of Mental Health then transformed that 
definition into “age-associated memory impairment” (AAMI). AAMI encompassed all 
memory impairments but it was unable to differentiate individuals at risk of progressing 
to pathological conditions in the future from those who were undergoing the process of 
normal aging. 28 In an effort to overcome these shortcomings, the International 
Psychogeriatric Association originated the term “age-associated cognitive decline.” The 
Canadian Study of Health and Aging also coined the term “cognitive impairment- no 
dementia” (CIND), which described individuals who were cognitively impaired but not to 
the extent of dementia. While this definition most closely resembles the definition of 
MCI, CIND encompasses a broader subset of individuals with lifelong cognitive 
impairment, static encephalopathy, and learning disabilities.28  
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 The term MCI first originated in the 1980s by Reisberg and colleagues to 
characterize individuals with a Global Deterioration Scale (GDS) rating of 3 and Clinical 
Dementia Rating Scale (CDR) of 0.5, although those numbers alone do not determine a 
specific diagnosis. 28 MCI is presumed to be the transitional stage between normal aging 
and early AD, and although memory impairment exists, cognitive function is generally 
normal and the criteria for dementia is not formally met.27, 28 MCI can be categorized 
into: amnestic MCI (memory loss is the main symptom) and non-amnestic MCI (memory 
loss is intact but other processing abilities like organizing, planning, reasoning, learning 
or judgement may not be). Amnestic MCI is the most common subtype with a prevalence 
of 10-14% in the elderly.31 
 In 1994, the Diagnosis and Evaluation of Dementia did not discuss guidelines for 
early detection of dementia. However, ample progress has been made since then in 
increasing attention to the evaluation and clinical monitoring of individuals with MCI. 
Literature reviews have found that there is insufficient data to make recommendations 
regarding cognitive screening of asymptomatic individuals but there is sufficient data to 
recommend evaluation and clinical monitoring of individuals with symptomatic MCI. 
The urgency for increased surveillance is due to increased risk of progression in 
individuals with MCI to AD when compared with similarly aged individuals in the 
general population.27  
 There have been a number of longitudinal, prospective, population and 
community- based studies investigating whether the presence of MCI predicts the 
development of AD dementia. 27 A recent review by the American Academy of 
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Neurology compiling a number of these studies showed that rate of conversion to AD 
dementia in individuals with MCI was 0.2% in the 65 to 69 age range and 3.9% in the 85 
to 89-year range. 27 Another large prospective study from Germany found that subjects 
with MCI progressed to dementia at rates of 7.2%- 10.2% per year.28 A meta- analysis of 
60 cohort studies found strong positive associations between progression from MCI to 
AD and the following risk factors: abnormal cerebrospinal fluid (CSF), phosphorylated  
(relative risk (RR)= 2.43, 95% CI= 1.70 to 3.48), hippocampal atrophy (RR= 2.59, 95% 
CI= 1.95 to 3.44), medical temporal lobe atrophy (RR= 2.11, 95% CI= 1.70 to 2.63) and 
entorhinal atrophy (RR= 2.03, 95% CI =1.57 to 2.62). Conversely, negative associations 
were found for high body mass index (BMI) (RR= 0.85, 95% CI= 0.76 to 0.96) and 
higher auditory verbal learning test delay score (RR= 0.86, 95% CI= 0.77 to 0.96).29 A 
limitation of this study was the inability to implement exposure assessment measures due 
to the large number of studies. Specifically, unmodifiable risk factors, such as lifestyle, 
alcohol use, smoking use, psychosocial factors, or any other variables that subjects were 
exposed to outside the controlled environment were not accounted for. Another limitation 
is that significant heterogeneity was found in ten of the meta-analyses that were 
performed due to differences between individual studies in study population 
characteristics, mean years of follow- ups, and the reporting of crude and adjusted risk 
estimates.29  
Pathophysiology of AD 
 AD is a highly complex and heterogeneous disease with biological, genetic and 
structural components of its pathophysiology. Histologically, it is classified by 
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intracellular neurofibrillary tangles (NFTs) and extracellular amyloid beta (A) plaques 
in the neocortex, hippocampus and other regions elemental in cognition. 6, 12 
Mitochondrial dysfunction and oxidative stress cause neurons to accumulate lipofuscin, 
which exacerbates neuronal dysfunction.13 The average time from diagnosis to death 
(which is dependent on disease stage, individual age and underlying comorbidities) is 
around 8 years but it can also last up to 20 years.6, 8 The cascade of events that occurs in 
the pathophysiology starts from a molecular basis. Amyloid precursor proteins (APP) aid 
in neuronal growth and recovery. Normally, APP is proteolyzed by enzymes alpha and 
gamma secretase. These fragments of APP are soluble and are able to be recycled. 
However, if gamma secretase is combined with beta secretase instead, APP becomes 
insoluble. This insoluble APP creates monomers of amyloid beta (A), which binds 
together to form an amalgamation of A. This is the main histological feature: an 
abnormal extracellular accumulation of A plaques in certain brain regions. An 
accumulation of plaques between neurons contributes to an impairment of brain 
signaling, loss of synaptic connections, and neuroinflammation, eventually leading to 
neuronal death. In a condition called amyloid angiopathy, A plaques can deposit in 
blood vessels in the brain, increasing the risk of hemorrhage. 6, 8,10   
 Neurons are held together by the cytoskeleton and the tau protein () prevents the 
tracts from disassembling. Neurofibrillary tangles consisting of  can deposit inside 
neurons. A plaque buildup initiates pathways inside the neuron that cease supporting the 
cytoskeleton resulting in clumps and tangles of . This also impairs neuronal signaling 
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leading to apoptosis. With increased numbers of neurons undergoing apoptosis, the brain 
starts to atrophy, gyri become narrower, sulci get wider, and ventricles appear larger. 6, 10 
 There are two distinct types of AD: familial and sporadic. Familial AD, the rarer 
type, usually affects people aged 30-60 and runs in families. It is caused by three known 
genes: Presenilin 1 (PS1), Presenilin 2 (PS2) and Amyloid Precursor Protein (APP). 
Sporadic AD (which represents more than 90% of AD patients) is much more common 
and affects individuals over age 55. The only gene that has been found to be linked with 
sporadic AD is the apolipoprotein E (APOE) gene, which mediates the processes of 
synapse formation, synaptic plasticity, destabilization of microtubules, and beta amyloid 
clearance. Humans are the only known species known to produce multiple alleles of the 
gene: APOE2, APOE3, and APOE4. The APOE2 isoform is relatively rare and may 
provide some protection. If AD dementia occurs in a person with APOE2, it most likely 
develops later in life than it would in someone with the APOE4 gene. The APOE3 allele 
is the most common allele and having this gene neither increases nor decreases the risk of 
getting AD dementia. APOE4, which is the strongest genetic risk factor, is associated 
with an earlier age of onset and results in a greater buildup of A plaques. If an 
individual possesses one copy of the E4 allele, AD onset is accelerated by 2-5 years. If an 
individual possess two copies, AD onset is accelerated by 5-10 years.9 
 The various isoforms of APOE proteins can bind with A forming APOE/A 
complexes that enhance plaque formation. These complexes make the clearance of A 
difficult, along with increasing the competition for the same clearance pathway. APOE4 
and A compete for the LRP1- dependent cellular uptake pathway in astrocytes, which 
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facilitates uptake and degradation within cells by modifying cytoskeletal enzymes. When 
APOE4 competitively inhibits LRP1/A binding, it contributes to an increase in A 
plaques. When APOE3 and APOE4 are in the same environment as A, they bind LDL 
receptors, exert internalization and bind to hippocampal neurons with greater affinity. 
This interaction also impacts the intracellular amyloid precursor protein (APP) recycling 
process, causing a greater increase in A load by enhanced A production.9, 16 
Risk factors of AD 
 Since there is currently no cure for AD, there has been an emerging approach 
towards mediating risk via modifiable risk factors. Any type of insult to the cerebral 
vasculature can serve as a risk factor contributing to cognitive impairments. These 
include: small and large cortical infarcts, vascular tortuosity, cerebral hemorrhage or 
ischemic stroke, hypo perfusion leading to cortical changes, and injuries or toxins that 
cause white matter changes. 6 Rodent models of neural ischemia due to cerebral hypo 
perfusion have showed an overexpression of p25 and cdk5 leading to increased levels of 
BACE1, which increase APP.6, 11,14, 16 
 Many of the risk factors found in cardiovascular disease are also applicable to 
AD. These include: obesity, decreased physical activity levels, metabolic syndrome, 
hypercholesterolemia, psychological stress, smoking, and alcohol abuse.6, 7, 14 In the 
Framingham Heart Study, researchers focused on studying the risk factors for 
atherosclerosis as they thought it would offer insight to potential modifiable risk factors 
of AD. They developed the Framingham Cardiovascular Risk Profile [FCRP], which 
included the individual’s age, gender, diabetes, smoking, treated and untreated systolic 
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blood pressure (SBP), total cholesterol, and high-density lipoprotein (HDL) cholesterol. 
Elevated scores of FRCP were associated with an increased risk for cardiovascular 
disease and smaller brain volume and increased white risk matter changes (evidenced by 
hyper intensities on imaging). FRCP scores and cognitive abilities had an inverse 
relationship establishing that cardiovascular disease increases parenchymal destruction.14, 
16 
 Another risk assessment model, called the Cardiovascular Risk Factors Aging 
and Dementia (CAIDE) risk score, showed how blood pressure, cholesterol and diabetes 
contributes to AD pathophysiology. Reduced cerebral blood flow is one of the 
contributors to AD pathophysiology. Chronic hypertension causes reduced cerebral blood 
flow through reduced vessel elasticity, thickening of vessel walls, and narrowing of the 
lumen. It also impacts the blood brain barrier (BBB) by causing cerebral edema and 
allowing the inflow of systemic elements into the brain. The longer hypertension affects 
the individual, the smaller the brain volume becomes (especially in the hippocampus). 16 
 Hypotension is also associated with a higher risk of AD as was evidenced in the 
Bronx Aging Study. Participants who had a diastolic blood pressure (DBP) of <70 mmHg 
and lower were twice as likely to get AD than those with DBP of >90 mmHg over a 
follow up of 2 years. The most reasonable explanation for this was that a DBP <70 causes 
decreased cerebral perfusion and this chronic ischemic state could lead to increased 
cerebral A accumulation.16  
 Unfortunately, there are some non-modifiable risk factors, such as: age, sex, 
family history, and presence of APOE4.9, 16 Conversely, the presence of protective risk 
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factors (which are modifiable) decrease an individual’s chances of getting AD. These 
include: cognitive reserve and mental activity, educational attainment and lifelong 
learning, cognitive leisure activities, physical activity, social engagement, mindfulness, 
optimism, and diet including omega-3 intake. 6 Studies have found that increased intake 
of plant-based foods,  increased fish intake due to increased amounts of omega 3, 
moderate red meat intake, reduced salt intake, and minimal alcohol intake can serve as 
protective factors.6, 7 
Diagnosis of AD 
 While there is no single diagnostic test that can diagnose AD, healthcare 
professionals use a variety of approaches to make a diagnosis. Typically, the patient is 
brought in by family members who are concerned about a decline in thinking, memory 
problems or forgetfulness. Initially, the healthcare provider will delve into the patient’s 
medical history asking questions on past medical history, psychiatric history, cognitive or 
behavioral changes, medication use, family history of similar symptoms, social history 
(diet, physical activity level, alcohol use or smoking). The healthcare provider will then 
assess reversible causes of memory loss, such as: depression, untreated sleep apnea, 
delirium, hypothyroid, other neurological disorders, vitamin deficiencies, and vitamin 
B12 deficiency.25 It is also important to rule out possible infectious causes. One of two 
highly sensitive neuropsychological screening tests, the Mini-Mental State Exam 
(MMSE) and Montreal Cognitive Assessment Test (MOCA) will be conducted which 
have subtle differences (Table 2). 1, 5 Both these tests are used to assess the overall 
activity of the higher cortical functions. In both the MMSE and MOCA, a maximum 
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score of 30 is considered normal, a score of 20-24 suggests mild dementia, 13-20 
suggests moderate dementia, and less than 12 indicates severe dementia.  
 
Table 2: Comparison of MMSE and MOCA in terms of the studied areas of 
cognition and scoring 5
 
Lastly, the medical workup includes brain imaging with MRI or CT to rule out other 
conditions, such as tumor, hemorrhage, stroke, or hydrocephalus, that may be causing 
memory loss but require different treatment. Some AD abnormalities include: 
hippocampal/temporal lobe atrophy in MRI, decreased amyloid/increased tau in CSF, and 
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amyloid plaques in PET scans. A metanalysis found that hippocampal volume can detect 
an average of 73% of MCI subjects who progress to AD. 20  
 
Neuropsychiatric (NPS) symptoms in AD 
 NPSs are among the earliest signs of cognitive decline and affect 97% of 
individuals with dementia, yet they are often under-recognized and difficult to treat. 23 
AD NPSs may manifest as a lack of emotional connection to people or things (apathy), 
disinterest, aggression, paranoia, impulsivity, depression, anxiety, disinhibition, 
irritability, motor disturbance, sleep disorder, appetite disorder, aberrant vocalization, 
motor problems, delusions, and hallucinations later in the course. 6, 10, 11, 16, 23  
 There is a prodromal phase of accelerated decline in multiple cognitive functions 
(otherwise known as mild cognitive impairment or MCI) before developing AD which 
can be last for as little as 6 months and up to 10 years. 18 According to the Alzheimer’s 
Association, about 15- 20% of people age 65 or older have MCI.11A cohort study done by 
Tarango et al found that among people with MCI, the presence of NPS may increase the 
risk of progression to AD dementia. 21 One MCI study found NPSs in 59% of participants 
and their presence forecasted faster progression from MCI to AD dementia in two large 
cohort studies. 23  
Depression and Sleep Dysfunction in MCI 
 There are 15-30% of patients with MCI who experience feelings of anxiety and 
depression and, among this group, the conversion rate of MCI to dementia can be as high 
as 50%. A compilation of literature reviews found that yoga improves depressive 
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symptoms by downregulating the hypothalamic axis and sympathetic nervous system 
leading to decreased cortisol levels, blood pressure and inflammatory markers.37  
Up to 45% of patients with MCI report sleep disturbance. These complaints 
include insomnia, sleep fragmentation, daytime sleepiness, and cognitive dysfunction. 
The connection between yoga, sleep and cognitive function is interlinked; therefore, yoga 
could be an ideal complement to the treatment plan. This was evidenced in a study done 
by Janelsins and colleagues who found that cancer patients who had undergone 2-24 
months of treatment and complained of sleep disturbances reported improved sleep and 
memory after participating in yoga. 37 Other benefits of yoga on sleep include: reduced 
sleep latency, improved sleep quality, and increased feelings of restfulness in the 
mornings. 37 
Treatment of AD 
 Currently, treatment for AD relies solely on symptomatic management and there 
is no definitive treatment that halts progression. Some medications exist but their benefits 
are small. There is an immense need for therapies to prevent and/or slow the progression 
of AD.25 Treatment is branched into pharmacologic therapy and non-pharmacologic 
(behavioral) interventions.  
Pharmacologic therapy 
 Currently, there are four Food and Drug Administration (FDA) approved 
medications available specifically for AD dementia. These treatments provide 
symptomatic relief but they do not modify the disease course. The medications are 
divided into two categories based on their respective mechanisms of action: 
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Cholinesterase inhibitors and NMDA (N-methyl-D-aspartate) receptor antagonists. While 
these drugs are not addictive, the following side effects have been reported: loss of 
appetite, nausea, vomiting, diarrhea, constipation, dizziness, headaches, and fatigue.25 
These drugs might be one strategy to temporarily aid with cognitive impairment but they 
may not work for everyone. Another short coming of these drugs is that their effects wear 
off over time. While the drugs are approved for specific AD stages (mild, moderate and 
severe), they are not approved for mild cognitive impairment. Clinical trials that have 
tested whether these drugs could prevent progression of the translational stage to AD 
have shown no lasting benefit.8 This is why there is an immense need to focus on 
effective lifestyle approaches to slow disease.  
 There are also new therapeutic approaches directed towards the pathogenesis of 
AD undergoing clinical trials. These include medications that are: anti-amyloid 
aggregates, anti-tau,  and secretase inhibitors, A vaccination, amyloid cholesterol-
lowering drugs, anti-inflammatories, and neuroprotective drugs. 2 
Cholinesterase inhibitors 
 In the cholinergic hypothesis a neurochemical feature of AD is a deficit in 
cholinergic transmission, which relates to memory impairment. Cholinesterase inhibitors 
were implemented in an effort to inhibit the synaptic enzymatic breakdown of 
acetylcholine (a neurotransmitter key to neurons involved with learning and memory) and 
improve cholinergic transmission. However, as increasing numbers of neurons die, the 
continued efficacy of these drugs discontinues. A review by the Quality Standard 
Subcommittee of the American Academy of Neurology concluded that despite the small 
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degree of benefit of treatment with acetylcholinesterase inhibitors, they should be first 
line treatment in patients with mild to moderate AD. There are four cholinesterase 
inhibitors that are approved by the FDA: Tacrin, Donepezil, Rivastigmine, and 
Galantamine. Data show that these cholinesterase inhibitors have similar efficacy in short 
term use but more data is needed to understand long term effects on disease progression. 
In 1/3 of patients, symptoms were shown to worsen in the first 6 months of treatment 
with a variable response to a second inhibitor. Clinical research studies have limited 
guidance on the safety of switching drugs. 8, 25, 26 
NMDA receptor antagonists 
 Increased extracellular amounts of glutamate, the main CNS excitatory 
neurotransmitter, can lead to exaggerated activation of NMDA receptors, which results in 
intracellular accumulation of Ca2+. This intracellular Ca2+ accumulation further results in 
neuronal death. Thus, Memantine, an NMDA- receptor antagonist, regulates the activity 
of glutamate and reduces the cascade of events (by partially blocking NMDA receptors) 
that would lead to the chronic increased influx of calcium and subsequent neuronal death. 
It can be used in moderate to severe AD although a systematic review by the Cochrane 
Dementia Group published that the trials were unable to detect clinically significant 
benefit due to their short nature and small sample size. 25, 26 
Treatment of NPS 
 Currently, only a few pharmacologic treatments for NPSs exist with proven 
efficacy and acceptable levels of risk, such as antipsychotics, antidepressants, 
benzodiazepines, cholinesterase inhibitors, and anticonvulsants.22 Antipsychotics (such as 
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Olanzapine, Aripiprazole, and Haloperidol) were found to have minimal efficacy on 
psychotic symptoms but were associated with several adverse side effects and an 
increased risk of death. 23  
Treatment of Depression and Sleep Disorder 
 Some studies have suggested that antidepressants may worsen the course of 
cognitive decline in certain patients and are even associated with QT interval 
prolongation. 23, 24 A meta-analysis of drug treatment versus placebo in patients with AD 
found insufficient evidence to help guide drug treatment of sleep problems in AD. 23 
Nonpharmacological interventions are considered the first line treatment but there has not 
been much real-world application due to insufficient funds to study their efficacy. 23 
Investigating the effects of yoga, electroconvulsive therapy (ECT), and drug therapy 
(Imipramine) for 4 weeks, a study done by Janakiramaiah et al found that respective 
remission rates were 67% for yoga, 93% for ECT, and 73% for drug therapy. 43 
 
EXISTING RESEARCH 
 While several treatment trials are advancing to determine which therapeutic 
measure can effectively halt progression from MCI to AD dementia, there has not been a 
clear answer. 27 The significance of early intervention in the MCI timeline is that sooner 
application of therapeutic interventions can prevent long term damage to the central 
nervous system.28 A systematic review found that no randomized controlled trials showed 
protective effects of dementia medication, anti- hypertensives, nonsteroidal anti-
inflammatory drugs, or aspirin.30  Despite inconsistencies in data on antioxidants in 
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cognitive function, there have been suggestions that vitamin E, vitamin C, gingko biloba 
and curcumin may be beneficial in early MCI stages to reduce oxidative stress levels. 31  
 Since no medications have been proven to effectively treat MCI, researchers have 
shifted their attention towards non-pharmacologic options. Certain non-pharmacologic 
interventions, such as moderate-intensity exercise, Mediterranean diet, social activities, 
and cognitive exercises have shown favorable results through observational research. 31 A 
study found that 6 months of a behavioral intervention consisting of regular intervals of 
increased heart rate improved executive function for patients with MCI without the cost 
and side effects of pharmaceutical therapies. 32 The participants in this randomized, 
controlled trial included 33 adults (17 women and 16 men) who ranged from the ages of 
55 to 85 years old and were diagnosed with MCI in memory disorder clinics by the 
Petersen criteria. The study aimed to analyze the impact of aerobic exercise on cognition 
in elderly adults who were had MCI. The subjects were randomized to one of two groups: 
either a high-intensity aerobic exercise group or a stretching control group. A fitness 
instructor supervised the aerobic exercise group and instructed exercises on treadmills 
and ellipticals for 45-60 mins 4 days a week for a duration of 6 months, while ensuring 
their heart rate was sustained 75%-85% of their heart rate reserve. Meanwhile, the 
stretching control group was supervised to maintain 50% or below of their heart rate 
reserve.32  
 Cognitive assessment testing measured both executive function and short-term 
memory at baseline, 3 months and 6 months. Executive function testing included the 
Trail Making Test (which consisted of drawing lines to connect alphanumeric stimuli that 
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were randomly placed on a page), the Stroop Color and Word Test (which tested 
selective attention and response inhibition using a computer), Task Switching (measured 
the ability to switch between tasks), and Symbol Digit Modalities (which tested 
processing speed by enabling subjects to draw symbols for a series of numbers). Short-
term memory was tested using Story Recall (which tested the ability of subjects to recall 
a narrative after a 30 min delay), List Learning (which tested the ability of subjects to 
hear 12 words and remember them across 3 trials), and Delayed-Match-To-Sample 
(which tested visual memory). Remarkable positive effects of aerobic exercise were 
assessed for Symbol-Digit Modalities (F1,26=4.18; P=.05), Verbal Fluency (F1,25=4.87; 
P=.04), and Trail Performance (F1,25=4.58; P =.04) compared to the stretching control 
group. A small sample size was a limitation of this study. Since the inclusion criteria of 
the study was limited to elderly adults without medical problems and those able to 
undergo physical exercise, the results might not be generalizable to population-based 
samples. Additionally, population-based samples will have less structure and supervision 
than this controlled trial did. There could also have been a potential misclassification bias 
if those in the control group exercised on their own time. This study found that non-
pharmacological treatment (aerobic exercise) was able to serve as a protective factor in 
preserving cognitive function in subjects with MCI.32 
 A single-blind randomized controlled trial by Zhu et al was designed to assess the 
effectiveness of a specifically designed moderate-intensity aerobic dance routine on 
cognitive function compared to the usual care in 56 patients with amnestic MCI for 3 
months. While both groups were counseled by physicians at baseline in promoting 
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healthy lifestyles, the treatment group attended a 35-minute dance session 3 times a week 
for 3 months. The dance session included head movement, side bending, knee bending, 
heel up, boxing, shoulder movement, kicking, square-stepping, and sculling exercises. 
The Wechsler Memory Scale- Revised logical memory test (WMS-R LM subtest), 
MoCA, Symbol Digit Modalities Test (SDMT), Trail Making Test (TMT), and forward 
and backward digit span tasks (DST) were used to measure outcomes.40  
 In order to detect an effect size of 0.75 SD, a sample size of 56 (28 per group) was 
required to achieve 80% power at the significance level of 0.05. Patients in the treatment 
group showed greater improvements in memory (95% CI 1.6, 5.1; p<0.05) and cognitive 
function (95% CI 0.8, 2.3; p<0.001) both at 3 months compared to the group that only 
received the usual care. Furthermore, these patients were followed up for another 3 
months after the discontinuation of the dance intervention and it was found that their 
previously obtained memory improvement had diminished, and quality of life was also 
improved compared to baseline (95% CI 1.1, 11.2, p<0.05). Only individuals with 
amnestic MCI were studied, so these findings may not be generalizable to those with 
non-amnestic MCI. Selection bias was also another limitation of this study because only 
elderly adults who were able to execute the aerobic dance routine were chosen. Those 
with increased sensitivity to fatigue or pre-existing medical conditions were unable to 
pass the screening criteria. However, these results confirm that the cognitive function of 
individuals with amnestic MCI in the treatment group substantially improved compared 
to the control group.40  
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 Existing research confirms the presence of NPS in patients with MCI and one 
study found that NPS occur with a prevalence between 43% and 59% in those patients. 
Patients with MCI and NPS have a four-fold higher risk of progression to dementia.21 
Studies have suggested that several NPS including anxiety, depression, apathy, and 
agitation have been linked to a higher risk of progression to AD. However, findings have 
still been inconsistent.34 A longitudinal population- based study by Palmer et al evaluated 
mood-related, depressive, and motivation-related symptoms in 185 people without MCI 
and 47 with MCI ages 75 to 95 from Stockholm, Sweden for 3 years. At the end of the 3-
year follow up, AD was diagnosed according to Diagnostic and Statistical Manual for 
Mental Disorders-III-R criteria. 33  
 More NPS occurred in individuals with MCI (36.2% mood, 36.2% motivation, 
and 46.8% anxiety) than in cognitively intact individuals (18.4% mood, 13% motivation, 
and 24.9% anxiety). At the 3- year follow up, 56.2% of individuals with multi-domain 
MCI developed AD compared to only 5.9% of individuals without baseline cognitive 
impairments.33 While investigating whether all NPS predicted progression to AD among 
individuals with MCI over 3 years, it was found that only the symptom of anxiety 
predicted AD in subjects with MCI (Figure 1). 33 





The risk of AD nearly doubled for every anxiety symptom (RR: 1.8, 95% CI: 1.2 to 2.7). 
Individuals with MCI who had problems with decision making had a 5-fold risk of AD 
compared to those without (RR: 5.6, 95% CI: 1.1 to 29). Moreover, individuals with MCI 
and persistent worrying also had a 5-fold increased risk (RR: 5.3, 95% CI: 18 to 15.6). 
About 6% of cognitively intact individuals, 40.9% of individuals with MCI without 
anxiety, and 83.3% of individuals with MCI and anxiety progressed to AD. Notably, this 
translated to a 30 times higher risk in individuals with MCI and anxiety (RR: 34.4, 95% 
CI: 13.9 to 85.8) than those cognitively intact. 33 
 This study suggests that the presence of anxiety symptoms with MCI enhances the 
predictive validity of identification of AD. This study was based off performance on 
neuropsychological tests and self-reported symptoms; moreover, it included data from a 
population-based study instead of a clinical sample, so the results have a higher 
likelihood of being generalizable to the general population compared to other studies that 
have used clinical samples. A limitation is that these results may not be representative of 
the general population due to the small sample size, and it is likely underpowered. 33  
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 Depression is another NPS that was found to be a precocious indicator of 
progression to AD in individuals with MCI. A prospective study done by Chan et al was 
conducted to assess the 2-year impact of NPS on clinical deterioration to AD in 321 
community-dwelling Chinese people aged 60 and older with MCI.34 Cognitive and 
functional assessment of the subjects was measured by a Chinese version of the MMSE, 
delayed recall of list learning of the Alzheimer’s Disease Assessment Scale- Cognitive 
subscale (ADAS-cog), Category Verbal Fluency Test (CVFT), and assessment by a 
geriatric psychiatrist with Clinical Dementia Rating (CDR). Of the 321 subjects, 270 
(84.1%) remained stable or improved, while 51 (15.9%) developed dementia over the 2 
years. These subjects presented with depression, apathy, and anxiety at baseline but 
27.5% of subjects with depression at baseline developed dementia in comparison with 
14.8% of those without depression at baseline. Dementia converters exhibited more 
delusions, agitation, depression, irritability, aberrant motor behavior and appetite changes 
and less apathy, anxiety, and night-time behavior disturbance (Figure 3). Particularly, 
depression and aberrant motor behaviors (although not as significant) at baseline were 
correlated with conversion to dementia in 2 years, whereas the other NPS prevalence was 
mild. 34  




 This study provides evidence that depression in individuals with MCI is an early 
predictor of progression to dementia. Additionally, it was recommended that further 
studies still need to assess whether effective management of NPS in MCI could prove to 
delay progression to dementia. The limitation of this study was that the small sample size 
included elderly individuals from Hong Kong. Cultural differences and underlying 
genetic or environmental factors could have affected the reporting of NPS, thereby 
introducing a potential bias. Additionally, the study had a short follow-up of 2 years 
which raises concerns of inadequately capturing all dementia converters. Thus, these 
results may not be generalizable to other cultural populations. 34 Lastly, the researchers 
might have been using incorrect statistics. This study used Chi square but many of the 
 
28 
comparisons would have small numbers in the cells. Thus, Fisher’s Exact might have 
been the more appropriate statistical test.  
 A 2-year cohort study done by Taragano et al evaluated three clusters of patients 
with MCI and NPS and examined their risk of progression to dementia: a severe cluster 
(agitation, anxiety, apathy, nighttime behaviors, inhibition), an affective cluster 
(depression, anxiety, irritability, nighttime behaviors), and an asymptomatic cluster. The 
sample consisted of 540 volunteers who were 60 years and older and diagnosed with MCI 
at an Alzheimer’s Disease Center (ADC). Data collection took place at the ADC between 
September 2005 and August 2013. The Neuropsychiatric Inventory Questionnaire (NPI-
Q), Mini-Mental State Examination (MMSE), and the Geriatric Depression Scale (GDS) 
were conducted at each visit. 21 
 Of the 540 individuals with MCI, 121 (22%) were diagnosed with dementia; those 
of the severe class had more than twice the risk of the asymptomatic class (2.69, CI: 1.65-
4.37) and the affective class had more than one and half times the hazard of the 
asymptomatic class (1.75, CI: 1.12-2.70). 21 This study highlights the finding that 
targeting patients with NPS from the severe cluster (agitation, anxiety, apathy, nighttime 
behaviors, inhibition) with effective management may decrease the risk of conversion to 
dementia due to its association, assuming that intervening on NPS modifies a similar 
underlying pathology to AD.  The sample also consisted of volunteers who were 
diagnosed with MCI after at least one visit where they were considered cognitively 
normal, so these results may not be generalizable to later stages of MCI. 21 
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 Yoga is an ancient mind body practice that has been identified as a 
complementary health approach by the National Center for Complementary and 
Integrative Health. Yoga has been affiliated with physical postures (asanas), breathing 
techniques (pranayama), and meditation (dyana). While there are several branches of 
yoga practices, Hatha yoga is the most common branch practiced in the US that 
encompasses physical posturer, breathing and meditation. Yoga is an exercise used and 
recommended by several people to approach and prevent health conditions such as, 
depression, anxiety, asthma, low back pain, cancer, cardiovascular disease, and insomnia. 
Yoga may improve multiple cognitive domains, such as attention, processing speed and 
verbal memory. 42  
 Mood disorders have been linked with reduced GABA levels and they have been 
shown to respond to drugs that increase GABA levels.36 A yoga intervention done by 
Gautam et al found the experimental group of yoga practitioners to have a 27% increase 
in GABA levels after a 60-minute session of yoga as opposed to change in GABA levels 
in controls after a 60 minute reading session. 35 These results show that the effects of 
yoga are comparable to pharmacologic treatment evidencing that a yoga intervention can 
prove to be as efficacious on depression as pharmacologic treatment with the benefit of 
no side effects. Eight studies in a literature review showed that yoga had beneficial 
effects on cognitive function in individuals with MCI by improving sleep, mood, and 
neural connectivity. 37 
  Mind-body interventions have increasingly been used to manage depressive 
symptoms but no studies have investigated the effects of a yoga intervention in 
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depressive symptoms in the elderly with mild cognitive impairment. While several 
studies have found an association between the presence of depression in individuals with 
MCI and progression to dementia, this randomized controlled trial will be the first yoga 






 This proposed study will be a randomized-controlled trial with two arms to assess 
the effects of a yoga intervention in improving depression symptoms and GABA levels in 
the brain. The control arm will not undergo a yoga intervention but will participate in 
walking twice a week for 9 months. The experimental arm will utilize a yoga intervention 
in combination with walking for the same duration of time. Both treatment groups will 
continue to receive normal baseline standard of care throughout the duration of the study. 
Patients will be assessed using the following validated standardized tools: Patient Health 
Questionnaire (PHQ-9), Geriatric Depression Scale (GDS), Hamilton Rating Scale for 
Depression (HAM-D), and Montreal Cognitive Assessment Test (MoCA). The HAM-D 
and GDS are both subjectively completed by the participant and the HAM-D is 
completed by a healthcare professional. Magnetic Resonance Spectroscopy (MRS), a 
non-invasive method to measure neurotransmitter concentrations in the brain, will be 
used to measure GABA levels throughout the experiment. 44 The subjects will be 
evaluated at baseline, at 3 months, and at 6 months to determine whether depression 




Study population, recruitment and sampling 
 Patients will be recruited from the Neurology and Family Medicine outpatient 
departments of several Boston hospitals including Boston Medical Center, St. 
Elizabeth’s, and Massachusetts General Hospital. A healthcare practitioner will have 
diagnosed the patients with both MCI using the Petersen criteria and depression using the 
DSM-5 criteria. Additionally, their depression will be poorly controlled over time, which 
are defined by persistent depressive symptoms (feeling sad, inability to concentrate, 
excessive feelings of guilt, extreme mood changes, fatigue, sleep changes, decreased 
interest and appetite levels, etc.) despite lifestyle modification and anti-depressant trials.  
 Patients who have exhausted their pharmacologic and non-pharmacologic 
treatment options for both MCI and depression will be asked to participate in this study at 
their next follow up visit with either the Neurologist or General Practitioner. If agreed, 
they will be asked to fill out a PHQ-9, GDS, and MoCA test. Patients with a MMSE or 
MOCA score of 20-26 will be asked to participate in the study to ensure that they are 
early in the process of MCI to be able to follow through with the yoga program. A score 
of <20 would make it difficult for patients to follow the steps of the session. Physicians 
will give their contact information to the research coordinators who will consequently 
reach out to the patients’ by phone to determine if they meet the inclusion criteria listed 
below. If they do, the patients’ will be asked to provide consent and will be enrolled into 
the study. 
  Prior to the start of the study, baseline MCI and depressive symptoms will be re-
evaluated in these patients. Each participant will undergo a medical evaluation to ensure 
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there are no contraindications that could lead to postural instability or difficulties 
following instructions. The first will be with their respective Family Medicine or 
Neurology practitioner to assess baseline symptoms and a research assistant with at least 
1-2 years of clinical research experience. The research assistant will explain the specific 
aims of the study with the participants and their families individually and answer all of 
their questions. After this meeting has been completed with all the participants, the 
intervention-based study will start in a few days. They will then be randomly assigned to 
the yoga group, and both groups will be given instructions regarding weekly text 
messages for walking reminders. 
 The inclusion criteria will include: (1) Patients of any gender between the ages of 
65-80 years old; (2) with a diagnosis of MCI according to a MoCA test score of 20-24 to 
ensure that they can follow commands properly; (3) with intact cognition according to a 
score of 8 or higher on the Short Portable Mental Status Questionnaire (SPMSQ); (4) a 
diagnosis of depression from the DSM-5 criteria; and (5) the ability to walk 
independently and perform yoga safely.  Patients must also have a means of 
transportation to assisted living facilities where the yoga intervention will take place and 
access to a cell phone on which they can receive text messages for reminders of biweekly 
walks. The exclusion criteria will include: (1) patients with a history of uncontrolled 
cardiovascular, postural, orthopedic, neurological, or pulmonary conditions that affect the 
individual’s ability to balance and think clearly; and (2) patients with a prior history of 
yoga training as it may bias the study.  
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 Based on a Cohen’s D of 0.54, the study will require a sample size of 110 with 55 
subjects in each arm to detect a significant difference by the student’s t test in 
improvement of depression symptoms. This is calculated with a beta of 0.2 and an alpha 
of 0.05. These numbers are generated based on the results from Eyre et al that found that 
level of improvement on the effects of depressed mood with kundalini yoga in 
individuals with MCI at 24 weeks using the Hopkins Verbal Learning Test Total Recall 
(HVLT) Total. 41 We predict that our intervention method will show similar or superior 
results in improvements in depression levels.  
Intervention 
 The intervention of this study is based on the study performed by Chen et al 
which investigated the effects of silver yoga exercises in the sleep quality, depression 
levels and mental health status in elderly individuals over 6 months, which found that 
improved mental health indicators after 3 months and were maintained throughout 6 
months. 40 Individuals who meet the inclusion criteria will be randomized into the two 
arms. A 40-minute yoga exercise program will be implemented twice a week for 6 
months as the intervention for the subjects in the experimental group in a senior assisted 
living facility. Each yoga session will have a trained yoga instructor who is specialized in 
geriatric exercise. The exercise program will include a warm up phase (10 mins) with 4 
postures to loosen up tight muscles, 7 gentle stretching postures (20 mins), and a 
relaxation phase (10 mins) with 4 postures. Inhalation and exhalation breathing 
techniques will be encouraged throughout the sessions and the yoga postures will be less 
arduous keeping in consideration the toleration and exhaustion levels of the elderly. Daily 
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walking will be implemented in all participants in both groups. Instructions on walking 
will be set via text message twice a week.  
Study variables and measures 
 Baseline demographics, such as age, gender, ethnicity, medical comorbidities 
(heart disease, lung disease, etc.), medications, level of physical activity and fitness, and 
pre-treatment scores for the PHQ-9, GDS, HAM-D, and PQSI will be obtained for all 
participants enrolled in this trial.  
 The dependent variable in this study will be level of depression, which will be 
measured by the PHQ-9, GDS, and HAM-D. The PHQ-9 consists of 9 questions that 
screens for the presence and severity of depression (see Appendix 1). The survey items 
ask about the patient’s level of interest in doing things, feeling depressed, difficulty 
sleeping, energy levels, eating habits, concentration abilities, self-perception, speed of 
functioning and thoughts of suicide. Responses can range from 0 (not at all) to 3 (almost 
every day). Total score can range from 0 to 27. A test of 10 or above is associated with 
the presence of depression and indicates that a treatment plan is needed.  
The GDS is a 30-item instrument (see Appendix 2), but there is also a short 15-
item instrument in case the other version proves difficult for patients to complete. 
Patients can answer either yes or no and one point is assigned to each answer. A score of 
0-9 indicates “normal”, 10-19 “mildly depressed”, and 20-30 “severely depressed.”  
The HAM-D will be administered by a healthcare professional (see Appendix 3). 
It asks questions in 21 areas with a choice of varying rating scores. A score of 0-7 
indicates “normal”, 8-13 indicates “mild depression”, 14-18 indicates “moderate 
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depression”, 19-22 indicates “severe depression”, >/= 23 indicates “very severe 
depression.”  
Sleep quality will be measured as a secondary outcome by using the Pittsburgh 
Sleep Quality Index (PQSI) with scores ranging from 0-21 and higher numbers 
correlating with worsening sleep quality. The independent variable of this study is 
participation in the yoga intervention.  
 
Data collection 
 The subjects will undergo assessments using the PHQ-9 and GDS, which will be 
individually filled out by the participant, and the HAM-D, which will be filled out by the 
healthcare provider. Each participant will also have blood work done to evaluate baseline 
values and MRS imaging to determine baseline GABA levels. 
 The clinical coordinator of the study will be responsible for scheduling and 
arranging follow up visits at baseline, 3 months, and 6 months with a clinical research 
assistant. The research assistant will provide each of the clinical assessments at all follow 
up visits. Either a family care physician or neurologist will be present at each of these 
follow-ups so they can assess symptoms and fill out the HAM-D. At subsequent follow 
up visits, scores from the prior visits will be assessed. The MoCA test will be assessed at 
each visit to ensure adequate levels of cognitive functioning. As long as the participants’ 
are not losing significant cognitive function, they will be allowed to continue in the study. 
If they do start to lose cognitive function, only data up to the point of loss of cognitive 
function will be included. In subsequent follow up visits, participants will complete the 
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assessments and speak to their relative healthcare practitioners about any difficulties or 
symptoms they are experiencing. Input on memory complaints or depressive symptoms 
will also be taken from their family members. At every follow up appointment, baseline 
MoCA and MMSE will be done.  
 To ensure adequate attendance for the entirety of the class, participants will be  
asked to sign in and sign out. In order to incentivize attendance, they will receive a 
member ID card that allows them to take part in the yoga classes free of charge. They 
will also be asked to keep track of their walking activity and any extraneous physical 




 To calculate the improvement in depression symptoms outcome, the data 
collected using the assessments will include the mean and standard deviation of the total 
score at baseline, 3 months, and 6 months. In order to compare the difference in 
depression scores between the study arms, the independent t-test will be used. 
Percentages of both treatment arm outcomes (improvement, no improvement or worse 
outcomes) will be summarized in a table. The comparisons among baseline, 3 month, and 
6 month outcomes will be conducted using the Chi square test showing percentages. To 
compare demographic information (such as age, race, sex, ethnicity, pre- intervention 
PHQ-9, GDS, and HAM-D scores) and assessment scores prior to the yoga intervention, 
means and standard deviations will be used to compare continuous variables and 
proportions will be used to compare categorical variables. Sleep and GABA levels will be 
analyzed by using the t-test.  
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Timeline and resources 
 
 This study will take place for a duration of 6 months (24 weeks) following 
recruitment. IRB approval is anticipated to take 6 months, recruitment should take 2-3 
months, and data analysis should take approximately 3 months. Approximately 5 yoga 
instructors and physical therapists with at least 1-2 years of experience will be recruited 
to teach the yoga routine. These instructors and therapists will be required to have 
worked with senior citizens in the past. The specified 40-minute yoga routine will be 
taught to the yoga instructors and physical therapists, and they will also be explained the 
safety protocols.  
 
 
Institutional Review Board 
 An outline of the detailed protocol and aims of the study will be submitted for full 
board review to the Boston University Medical Campus Institutional Review Board 






 The results of this study will provide information about the possible applicability 
of a non-pharmacologic therapeutic intervention in improving depression in individuals 
with mild cognitive impairment. Yoga has been associated with remarkable outcomes for 
improving depression and sleep outcomes in individuals with a wide variety of medical 
conditions compared to pharmacological interventions. The current pharmacologic 
therapeutic interventions aimed at alleviating depression and other neuropsychiatric 
symptoms of MCI are associated with a wide range of serious side effects and there has 
not been much investigation into non-pharmacologic interventions. This study is the first 
study to measure the outcome of yoga in depression symptoms in individuals with mild 
cognitive impairment. Since there is a strong association between depression and quality 




 Depression and mild cognitive impairment both lack an ability to be biologically 
tracked; they must be evaluated using standardized assessments. A limitation is that 
although the PHQ-9 and GDS are generally used, their ability to correctly identify 
depression compared to some established criteria has not been thoroughly investigated. 
For instance, no studies in the US have investigated the diagnostic accuracy of the PHQ 
compared to the gold standard, the Structured Clinical Interview for DSM-5 (SCID). 
However, SCID was not used in this study due to its increased length of completion time, 
which may not be sustainable for the elderly population. False positives and false 
negatives can occur in these assessments which can also be problematic. On the contrary, 
strengths of these assessments are that they are simple and cost-effective tools.  
 Patient compliance and adherence to the yoga intervention may also be another  
 
limitation. The population of the study is elderly with mild cognitive impairment and  
 
depression among other neuropsychiatric symptoms so they may display decreased 
 
 levels of motivation at times. Moreover, they may fatigue more easily and have lower  
 
levels of physical stamina. Yoga has been shown to boost endorphin levels and the ability 
 
 to engage in social activity with their peers and instructors may boost motivation.  
 
 The strengths of this study include the wide range of diverse ethnic, racial and  
socioeconomic backgrounds of the patients, which will allow for the results of the study 
to be generalizable to diverse population-based communities. While the participants will 
continue to receive standard of care by their practitioners, they will also be on 
pharmacological therapy to avoid potential biases if their depression or MCI become 
resistant to treatment.   This is contrary to other studies that have evaluated the use of 
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non-pharmacologic treatment in individuals with mild cognitive impairment and 
depression where the participants have not been simultaneously taking both 
pharmacologic therapy and non-pharmacologic therapy.  
Summary 
 MCI is the translational stage in the progression to dementia and it is associated 
with NPS, including depression. Research has found that the presence of these NPS is 
associated with eventual progression to AD dementia and targeting them could prevent 
progression to dementia, if the intervention targets underlying shared pathophysiologies 
of the conditions. Existing pharmacologic treatment for NPS is replete with adverse side 
effects and minimal resolutions. Research has also found that yoga has been effective in 
improving depression symptoms in individuals with various kinds of diseases but these 
have been limited in study duration, design and demographics of participants. Yoga has 
also been chosen as an intervention for this study because it fosters the ability to build 
relationships and interact in a social setting, which may increase GABA levels in the 
brain. This study will be the first to investigate the effects of yoga on depression in 
individuals with mild cognitive impairment. The population in this study will be from 
various racial, ethnic and socioeconomic backgrounds, on pharmacologic agents for 
depression and MCI, and with varying levels of depression. They will be randomized into 
a treatment group, which will be exposed to a biweekly yoga intervention with walking, 
and a control group, which will be exposed to just walking weekly, both for a total 
duration of 9 months. Thus, the potential for bias will be accounted for by eliminating the 
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possibility of participants being resistant to treatment for depression and outcomes will be 
measured using standardized assessments, the PHQ-9, GDS and HAM-D. 
 
Clinical and/or public health significance 
 After heart disease and cancer, AD is the 3rd most expensive disorder in the 
country. It is the only cause of death in the top 10 that cannot be cured, reversed or 
slowed and approximately 100,000 patients die of AD each year. There are significant 
economic, social and health care burdens to prevent, diagnose, treat and manage AD 
dementia.19 As per the CDC, the costs of treating AD in 2010 were projected to be 
between $159 and $215 billion.17 However, by 2040, these costs will jump to between 
$379 and more than $500 billion annually.3, 17, 19 Total costs include: direct costs 
(medications, physician visits, home health aides), indirect costs (caregiver lost 
productivity), and intangible costs (suffering and decreased quality of life endured by 
caregivers). A Medicare study showed that each comorbid condition in patients with AD 
(which also costs more to manage) was associated with a higher cost ($10,435) than in 
patients without AD ($526). 3, 19   
 Healthcare systems are increasingly examining non-pharmacologic interventions 
as a more effective option. Exercise has been linked with improving cognition and 
reducing depression levels in individuals with MCI. Studies have examined the 
interventions of aerobic exercises in patients with MCI, but the use of yoga in individuals 
with MCI and depression have yet to be studied. Commitment to exercise regimens can 
be difficult for the elderly with MCI, and high intensity aerobic exercise can prove to be 
challenging. Studies have linked yoga with high enjoyment levels and feasibility levels 
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which increase the likelihood of the elderly being consistent with the exercise. If this 
study proves to utilize yoga to reduce depression levels in patients with MCI, healthcare 
professionals could recommend yoga exercises to target depression levels that have been 
associated with eventual progression of MCI to AD dementia. Thus, this highlights the 
importance of enforcing effective non-pharmacologic interventions both for the 
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